1998
A phase I/II trial of nimodipine for HIV-related neurologic complications
Navia B, Dafni U, Simpson D, Tucker T, Singer E, McArthur J, Yiannoutsos C, Zaborski L, Lipton S. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998, 51: 221-228. PMID: 9674806, DOI: 10.1212/wnl.51.1.221.Peer-Reviewed Original ResearchConceptsAIDS dementia complexVoltage-dependent calcium channel antagonistsPhase I/II trialSevere AIDS-dementia complexHigh-dose armPhase II studyFurther clinical trialsCalcium channel antagonistsNPZ-8Adjuvant treatmentAntiretroviral therapyII trialNeurologic complicationsNeuropsychological z scoresNeuronal injuryHIV infectionPeripheral neuropathyTreat analysisCSF levelsDementia complexImmune activationClinical trialsNeurologic disordersChannel antagonistsPossible efficacy
1990
HIV-1 Coat Protein Neurotoxicity Prevented by Calcium Channel Antagonists
Dreyer E, Kaiser P, Offermann J, Lipton S. HIV-1 Coat Protein Neurotoxicity Prevented by Calcium Channel Antagonists. Science 1990, 248: 364-367. PMID: 2326646, DOI: 10.1126/science.2326646.Peer-Reviewed Original ResearchConceptsCalcium channel antagonistsHuman immunodeficiency virus type 1Channel antagonistsIntracellular calciumNeuronal injuryDihydropyridine calcium channel antagonist nimodipineCalcium channel antagonist nimodipineImmunodeficiency virus type 1Rodent retinal ganglion cellsGp120-induced increaseChannel antagonist nimodipineRetinal ganglion cellsIntracellular free calciumDose-dependent fashionGp120 envelope proteinVirus type 1Envelope proteinAntagonist nimodipineControl immunoglobulinGanglion cellsHippocampal neuronsProtein gp120Viral envelope proteinsExtracellular calciumNeuronal toxicity